摘要
目的评价妊娠中期孕妇血清(AFP/β-hCG)二联法筛查在唐氏综合征、18-三体综合征和神经管缺陷的临床应用价值。方法对35961例孕14-21周的孕妇采用时间分辨免疫荧光法(DELFLA)进行血清AFP和Free-βHCG浓度的检测,结合孕周、体重、年龄等因素,通过风险评估软件进行风险评估。将筛查结果与B超、羊水、新生儿检查结果对照。结果35961例孕妇中筛查出唐氏综合征高危妊娠1856例,筛查阳性率为5.16%(1856/35961),经羊水染色体核型分析确诊10例唐氏综合征患儿;18-三体高风险者170例,筛查阳性率为0.47%(170/35961),经羊水染色体分析确诊5例;神经管缺陷高危者259例,筛查阳性率为0.72%(259/35961),其中确诊为神经管缺陷胎儿61例。结论通过AFP/β-hCG产前筛查可减少缺陷儿的出生,具有明显的经济效益和社会效益,是落实优生优育政策非常有效的技术手段。
Objective:To evaluate the clinic value of the double marker prenatal screening system for Down′s syndrome (DS),trisomy 18 and neural tube defects (NTD). Methods: DELFLA double marker reagents are used to test the concentrations of AFP and β-HCG in the serum of 35961 middle period pregnant women whose were pregnant for 14-21 weeks. With factors of children weeks,avoirdupois,age and so on,we evaluated the risk with risk evaluation software. Then compared the results whit type-B ultrasonic ,amniocentesis ,and results of the newborn′s examination. Results: Among the high risk cases of 36951,1856 (5.16%) cases indicate DS and 170 (0.47% ,1856/35961) cases suggest 18-Ⅲ. By amniocentesis,10 cases were diagnosed Down′s syndrome;5 cases were diagnosed 18-Ⅲ;259 (0.72% ,259/35961) examples with neural tube defect high risk were checked.61fetuses with neural tube defect were diagnosed. Conclusion: By the prenatal screening of blood serums AFP /β-hCG,it decreased the rate of birth defects. Prenatal screening has distinct economic and social benefit ,and it is a very effective technic means to carry out our country′s prepotency policy.
出处
《中国优生与遗传杂志》
2010年第2期47-49,共3页
Chinese Journal of Birth Health & Heredity